Overview

Ph 2 Open Label Study of GC4419 to Reduce SOM Associated With Chemoradiotherapy for Head and Neck Cancer

Status:
Active, not recruiting

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

GTI-4419-202 is a Phase 2 open-label study of the effects of GC4419 when administered IV in combination with IMRT/cisplatin to up to 70 subjects with head and neck cancer, who are at high risk for SOM.

Phase:

Phase 2

Details

Lead Sponsor:

Galera Therapeutics, Inc.

Treatments:

Avasopasem manganese